Efficacy and performance of the new pipeline vantage flow diverter stent with shield technology: Short-term results of a single-center experience.

ObjectivesThe aim of this study is to investigate and delineate the reliability and efficacy of the new Pipeline Vantage (PV). The flow diverter device was recently introduced presenting the innovative shield technology.MethodsThis retrospective study included 21 patients with 22 unruptured intracranial aneurysms, all of whom were treated with the PV device at our institution between January 2022 and January 2023. Patient demographics, aneurysm morphology and location, periprocedural strategies, treatment approaches, and occlusion status at follow-up (up to one year) were retrospectively analyzed.ResultsNineteen of the aneurysms (86.36%) were treated solely with the PV device and three (13.63%) were treated in combination with coil embolization. Two patients (9.52%) were expired, one related to a subarachnoid hemorrhage occurred during treatment and the second one after a successful treatment on follow-up, due to the existence of concomitant disease, not related to the aneurysm itself. The mean time of follow-up on the treated aneurysms was 7.4 months. In 81.81% (18 aneurysms) of the cases presented, a complete aneurysm obliteration was achieved on the last follow-up imaging.ConclusionsIn this initial experience, the PV flow diverter demonstrated favorable short- and mid-term outcomes in the treatment of intracranial aneurysms. While the overall complication profile was acceptable, the occurrence of a periprocedural mortality reflects the inherent procedural risks of neurointervention, even under meticulous technique. However, short-term results should be balanced with caution and supported by robust research to demonstrate the long-term safety and efficacy of the device.Advances in knowledgePV the successor of the novel Pipeline device showed promising short-term results.